Focused On-demand Library for Protein MTSS 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q765P7

UPID:

MTSS2_HUMAN

Alternative names:

Actin-bundling with BAIAP2 homology protein 1; MTSS1-like protein

Alternative UPACC:

Q765P7; A6NJI7; Q9BUA8

Background:

Protein MTSS 2, also known as Actin-bundling with BAIAP2 homology protein 1 or MTSS1-like protein, plays a crucial role in plasma membrane dynamics. It enhances PDGF-mediated membrane ruffle and lamellipodia formation in fibroblasts through RAC1 activation, and may also be involved in actin bundling. This protein's activities are pivotal for cellular morphology and motility.

Therapeutic significance:

Protein MTSS 2 is linked to Intellectual developmental disorder with ocular anomalies and distinctive facial features, a condition marked by developmental delays, intellectual disability, and various physical anomalies. Understanding the role of Protein MTSS 2 could open doors to potential therapeutic strategies for this disorder.